ADMA Biologics, Inc. (ADMA) Q2 2019 Earnings Results

ADMA Biologics Misses on EPS, Stock Up 3.58%

ADMA Biologics reported a loss per share of $0.25, but the stock rose by 3.58% following the earnings announcement. Investors may be reacting positively to management's comments about product development and regulatory milestones, despite the lack of revenue details and guidance. The stock's increase suggests that market sentiment remains hopeful for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.25	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about future prospects. They emphasized their focus on product development and regulatory approvals.

Management expressed confidence in ongoing product development.

They highlighted the importance of upcoming regulatory milestones.

ADMA Biologics Misses on EPS, Stock Up 3.58%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Up 3.58%

Key numbers

Management commentary